Reply from the Author
Safety of heparin in acute ischemic stroke
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Reply from the Authors: We thank Drs. Lee, Lodder, Hart, and colleagues for their interest in our recent article. A few comments, however, seem pertinent for its best comprehension.
Our article breaks new ground by analyzing the interactions between death, stroke severity, and hemorrhagic complications, using the most appropriate statistical methods available. Apparently, our critics based their arguments on two main points: (1) The low recurrence rate of embolic stroke, and (2) the mortality rate due to hemorrhagic complications.
First, on the low recurrence rate of embolic stroke, estimated by some authors to be approximate 2 to 4%. [2,4] However, it must be noted that other series have reported a greater risk or recurrent embolic stroke. [10,14] Lodder et al. [10] estimated a risk greater than 8%, and Halperin and Hart, [9] estimated a 15% to 20% stroke recurrence rate within the first year alone. More recently, Yasaka et al [12] found recurrent embolization within the first 2 weeks after stroke to be 20.3% and the recurrent events most frequently occurred during the first 2 days after the initial stroke. In addition, mortality in patients who recurred was 19.6% compared with 8.8% in patients with no stroke recurrences. Also, Darling et al [13] reported the rate of recurrent thromboembolism within 14 days to be 19.6% in 148 patients with valvular and NVAF, and …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Views & Reviews
Potential new uses of non–vitamin K antagonist oral anticoagulants to treat and prevent strokeShadi Yaghi, Hooman Kamel, Mitchell S.V. Elkind et al.Neurology, July 17, 2015 -
Article
Recurrent thromboembolic events after ischemic stroke in patients with cancerBabak B. Navi, Samuel Singer, Alexander E. Merkler et al.Neurology, May 21, 2014 -
Article
Age- and sex-specific analysis of patients with embolic stroke of undetermined sourceGeorge Ntaios, Gregory Y.H. Lip, Konstantinos Vemmos et al.Neurology, July 07, 2017 -
Article
A tool to identify patients with embolic stroke of undetermined source at high recurrence riskGeorge Ntaios, Georgios Georgiopoulos, Kalliopi Perlepe et al.Neurology, October 29, 2019